Galanthamine-d3 (hydrobromide)

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Acharya Balkrishna, et al. Anti-Acetylcholinesterase Activities of Mono-Herbal Extracts and Exhibited Synergistic Effects of the Phytoconstituents: A Biochemical and Computational Study. Molecules. 2019 Nov; 24 (22) : 4175.|[3]Balpreet Matharu, et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci. 2009 May 15;280 (1-2) :49-58.|[4]Debby Van Dam, et al. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) . 2005 Jun;180 (1) :177-90.|[5]Johan Monbaliu, et al. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Arzneimittelforschung. 2003;53 (7) :486-95.|[6]L J Scott, et al. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60 (5) :1095-122.|[7]Marek Samochocki, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Pharmacol Exp Ther. 2003 Jun;305 (3) :1024-36.